Skip to main content

Month: June 2023

Aurora Spine Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Carlsbad, Calif, June 28, 2023 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System. The commencement of the enrollment of patients indicates that the company has received all necessary approvals to launch the study, which will initially include data from 40 single level and 40 multiple level subjects. Mr. Trent Northcutt, Aurora’s President, CEO and co-founder, stated, “The launch of the study is exciting news for Aurora and its DEXA platform technology. With this multicenter study now underway, we will be able to collect and provide important data to the medical...

Continue reading

Aben Minerals Provides a Corporate Update

Vancouver, BC, June 28, 2023 (GLOBE NEWSWIRE) — Aben Minerals Ltd. (TSX-V: ABM) (OTCQB: ABNAF) (Frankfurt: R26) (“Aben” or “the Company”) is pleased to provide a Corporate update on the affairs of the Company and its Projects. The Company, going forward, is planning to advance the flagship Justin Gold Project in the Yukon that adjoins Seabridge Gold’s 3 Aces Project. The Company plans to follow up on the greenfield discovery by Aben in 2011 and 2012 at the Justin POW Zone with a highlight drill intercept of 1.25 g/t Au over 60.0m including 2.47 g/t Au over 21.0m. The Company is currently applying for a new multi year Class 3 Quartz Exploration permit to allow for advanced exploration including diamond drilling at the Justin Project. Aben also announces the resignation of Simon Dyakowski from the board of directors effective immediately....

Continue reading

Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that long-term clinical study results from the U.S. ANAVEX®2-73-RS-001 (NCT03758924) study demonstrate disease modifying effect of ANAVEX®2-73 (blarcamesine) for adult patients with Rett syndrome. Usually, symptomatic therapies treat the symptoms of the disease but do not address the underlying cause of the disease. Disease-modifying therapies target the underlying cause of the disease. ANAVEX®2-73 (blarcamesine) is an orally available,...

Continue reading

Bullet Blockchain Expands Presence in the Cryptocurrency Market With Acquisition of Bitcoin ATM Fleet

 “Bullet ATM” Branded ATM Machines Will be Integrated With the Company’s Patented Technologies, Making Them the First Licensed Bitcoin ATM Network in North America RENO, NV, June 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Bullet Blockchain, Inc. (“BULT” or the “Company”), (OTC: BULT), a pioneering software development and SaaS company at the forefront of blockchain technologies and Web 3.0, is pleased to announce the successful completion of a strategic transaction to acquire a fleet of Bitcoin ATMs. As the owner and licensor of two Bitcoin ATM patents, the Company is excited to expand its offerings and provide greater accessibility to cryptocurrencies. As previously announced, BULT acquired an intellectual property portfolio consisting of Bitcoin ATM Patents (the “IP Portfolio”). BULT’s IP Portfolio will be integrated into...

Continue reading

Avicanna Provides Corporate Update and Preliminary Q2 Results

TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce a corporate update and preliminary financial results of Q2-2023. The update includes:Q2-2023 Revenues: Q2-2023 revenues of approximately $3.3M representing an approximately 200% increase over Q1-2023 revenues of $1.2M, this includes approximately $2.5M in sales arising from the Medical Cannabis by Shoppers platform since May 29, 2023.Medical Cannabis By Shoppers: On May 29, 2023, the Company announced that the definitive Asset Purchase Agreement with Shoppers Drug Mart Inc. for Avicanna to acquire the Medical Cannabis By Shoppers business was fully...

Continue reading

Amesite Announces V6.3, with Streamlined, AI-First Infrastructure to Enable Customization and Scale for Its Enterprise Customers

DETROIT, June 28, 2023 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for education, business, and government markets, announces today that V6.3 will be available to its Customers on July 10, 2023. “We are thrilled to announce the roll out of our latest update – V6.3 – utilizing a streamlined, AI-first infrastructure. Our enterprise customers are in a phase of rapid expansion, and they need reliable solutions that support their growth,” said Amesite Founder & CEO, Dr. Ann Marie Sastry. “Our AI-driven platform features can now be delivered with even greater scalability and affordability, along with greater degrees of customization, to meet our Customers’ needs.” By implementing Azure’s cloud solutions, Amesite has...

Continue reading

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug development Dr. Chong to lead clinical development of InflaRx’s portfolio of C5a/C5aR inhibitorsJENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affairs and overseeing the launch of new drugs across multiple geographies. She will be responsible for all clinical developments related to InflaRx’s...

Continue reading

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA

SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). “We are pleased to obtain the NMPA’s acceptance of our NDA for repotrectinib, which further supports repotrectinib as a potential best-in-class treatment for patients with ROS1-positive NSCLC in China. There is a significant unmet need for these patients given the limited durability of benefit, the emergence of resistance to approved therapies and eventual tumor progression,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development...

Continue reading

Purpose Investments Inc. Announces Final June 2023 Distribution Rate for Purpose Cash Management Fund and Purpose USD Cash Management Fund

TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final June 2023 distribution rate for Purpose Cash Management Fund and Purpose USD Cash Management Fund. The following table reflects the final distribution amounts. The ex-distribution date is June 29, 2023.Open-End Fund TickerSymbol Final distributionper unit Record Date Payable Date DistributionFrequencyPurpose Cash Management Fund – ETF Units MNY $0.3884 06/29/2023 07/10/2023 MonthlyPurpose USD Cash Management Fund – ETF Units MNU.U US $ 0.4253 06/29/2023 07/10/2023 MonthlyAbout Purpose Investments Inc. Purpose Investments Inc. is an asset management company with more than $16 billion in assets under management. Purpose Investments has an unrelenting focus on client-centric innovation and offers a range of managed and quantitative...

Continue reading

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate. In August 2022, Blue Water announced plans to explore the development of its novel monkeypox vaccine candidate by presenting monkeypox antigens within the S&P platform. Following successful integration of selected antigens into the platform, mice were immunized with the vaccine candidate and analyzed for antibody levels in the blood. Initial data show that mice were able to generate an immune response following vaccination and antibodies...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.